Androgen deprivation therapy and androgen receptor pathway inhibitors increase the risk for cardiovascular events, hypertension, and diabetes in patients with prostate cancer.
Prostate cancer therapies increase cardiovascular risk, highlighting the need for better cardiovascular risk factor management in this population.
Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor pathway inhibitors, including androgen receptor antagonists and cytochrome P450 17A1 inhibitors confer incremental risks for hypertension and cardiovascular events to androgen deprivation therapy. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists compared with agonists requires confirmation in well-designed randomized trials.
Leong et al. (2024) conducted a review in Prostate cancer. Androgen deprivation therapy and androgen receptor pathway inhibitors was evaluated. Androgen deprivation therapy and androgen receptor pathway inhibitors increase the risk for cardiovascular events, hypertension, and diabetes in patients with prostate cancer.